Dysport Now FDA Approved for Wrinkles, Dystonia
Last week, the Food & Drug Administration granted clearance to Medicis Pharmaceutical for their new wrinkle reducer, Dysport. Plastic surgeons and dermatologists may have the drug available for cosmetic use in just 30 – 60 days.
Dysport will compete with Botox, as both drugs perform the same basic function – neuromuscular blocking to relax and prevent wrinkles. Dysport however, is said to be more diluted than Botox and thus more cost effective for providers. The recent FDA approval of dysport also came with a unique warning label describing the risks associated with the botulinum toxin.
Rather than rebranding the drug ‘Reloxin’ as planned, Medicis decided to retain its original European name, Dysport
The April 30th announcement coincided with a 3 percent drop in Allergan’s (maker of Botox) shares, and a 14 percent increase of Medicis’ shares. Analysts and industry professionals expect Dysport to carry a slightly lower price tag than Botox, and say it could capture as much as 30 percent of the current market.
For more information on wrinkle treatments in Chicago and Munster, Indiana see our homepage.